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Introduction {#ehf212339-sec-0004}
============

 {#ehf212339-sec-0005}

Functional mitral regurgitation (MR) is a frequent complication in heart failure patients owing to left ventricular remodelling processes causing papillary muscle dislocation and leaflet tethering, and it is associated with an adverse prognosis.[1](#ehf212339-bib-0001){ref-type="ref"}, [2](#ehf212339-bib-0002){ref-type="ref"} Surgical correction for functional MR is controversial with no consistent outcomes for patients in terms of survival and quality of life and reports of suboptimal outcomes and significant perioperative mortality.[3](#ehf212339-bib-0003){ref-type="ref"}, [4](#ehf212339-bib-0004){ref-type="ref"} In addition, a large number of patients with functional MR are not referred for surgery, and many other patients are rejected for open‐heart surgery because of a predicted high surgical risk or co‐morbidities.[5](#ehf212339-bib-0005){ref-type="ref"} Thus, when surgical risk is prohibitive, percutaneous mitral valve repair (PMVR) using the MitraClip system can be considered a valid option for patients with functional MR who remain symptomatic despite optimal medical therapy.[6](#ehf212339-bib-0006){ref-type="ref"} Recently, several studies have confirmed that MitraClip procedure is safe with sustained improvement of haemodynamic and functional status even in patients with advanced heart failure, but its impact on survival has not been established.[7](#ehf212339-bib-0007){ref-type="ref"}, [8](#ehf212339-bib-0008){ref-type="ref"}, [9](#ehf212339-bib-0009){ref-type="ref"}, [10](#ehf212339-bib-0010){ref-type="ref"}, [11](#ehf212339-bib-0011){ref-type="ref"} To date, there are few non‐randomized studies that globally report better survival outcome of PMVR than of conservative treatment in patients with left ventricular dysfunction and functional MR.[12](#ehf212339-bib-0012){ref-type="ref"}, [13](#ehf212339-bib-0013){ref-type="ref"}, [14](#ehf212339-bib-0014){ref-type="ref"}, [15](#ehf212339-bib-0015){ref-type="ref"}, [16](#ehf212339-bib-0016){ref-type="ref"}, [17](#ehf212339-bib-0017){ref-type="ref"}

Therefore, we performed a meta‐analysis of observational studies selecting all‐cause mortality as primary outcome, in order to compare PMVR with MitraClip system combined with medical therapy to medical therapy alone for treatment of severe functional mitral regurgitation.

Methods {#ehf212339-sec-0006}
=======

Search methods and resources {#ehf212339-sec-0007}
----------------------------

The present research was elaborated according to current guidelines, including the recent Preferred Reporting Items for Systematic Reviews and Meta‐Analyses amendment to the Quality of Reporting of Meta‐analyses statement and recommendations from The Cochrane Collaboration and Meta‐analysis of Observational Studies in Epidemiology.[18](#ehf212339-bib-0018){ref-type="ref"}, [19](#ehf212339-bib-0019){ref-type="ref"}, [20](#ehf212339-bib-0020){ref-type="ref"} Pertinent articles were searched in PubMed, Cochrane, and Google Scholar for the following terms: 'mitral regurgitation' and 'MitraClip' and 'medical therapy'. Two reviewers (C. G. and F. D. A.) independently reviewed all papers, with disagreements resolved by consensus. Inclusion criteria were (i) human studies, (ii) studies comparing MitraClip vs. medical therapy, (iii) follow‐up longer than 1 year, (iv) at least 80% of the patients with functional MR, and (v) studies with multivariate adjustment. In the case of duplicate reporting, the manuscript with the largest sample of patients was selected.

Data abstraction {#ehf212339-sec-0008}
----------------

The following data were independently abstracted by two unblinded reviewers (C. G. and F. D. A.) on pre‐specified electronic forms: authors, journal, year of publication, location of the study group, baseline, and procedural features. The corresponding authors of the relevant studies were queried for required quantitative details not in the published manuscripts. When available, only data for patients with functional MR were included.

Endpoints {#ehf212339-sec-0009}
---------

All‐cause death was the primary endpoint, while re‐hospitalization for cardiac cause was the secondary one. At patient level, subgroup analysis stratified according to age, presence of implantable cardioverter defibrillator/cardiac resynchronization therapy, cardiomyopathy aetiology, left ventricular ejection fraction, and volumes was also performed.

Quality study evaluation {#ehf212339-sec-0010}
------------------------

The quality of included studies was independently appraised by two reviewers (C. G. and F. D. A.), with disagreements resolved by consensus. Design of the study (multicentre or not), area of enrolment, and kinds of multivariate analysis were collected.

Statistical analysis {#ehf212339-sec-0011}
--------------------

Continuous variables are reported as mean (standard deviation) or median (first and third quartiles). Categorical variables are expressed as *n* (%). Statistical pooling for incidence estimates was performed according to a random‐effects model with generic inverse‐variance weighting, computing risk estimates with 95% confidence intervals (CIs), using RevMan 5.2 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Hypothesis testing for superiority was set at the two‐tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the two‐tailed 0.10 level and based on the Cochran *Q* test, with *I* ^2^ values of 25%, 50%, and 75% representing mild, moderate, and severe heterogeneity, respectively.

Results {#ehf212339-sec-0012}
=======

Study selection {#ehf212339-sec-0013}
---------------

The flow chart is shown in *Figure* [*1*](#ehf212339-fig-0001){ref-type="fig"}. The electronic search yielded 351 citations that were initially evaluated for eligibility in title and abstract levels. Once duplicate and irrelevant publications had been removed, six reports were evaluated in full text for eligibility and were finally used in the current meta‐analysis.[12](#ehf212339-bib-0012){ref-type="ref"}, [13](#ehf212339-bib-0013){ref-type="ref"}, [14](#ehf212339-bib-0014){ref-type="ref"}, [15](#ehf212339-bib-0015){ref-type="ref"}, [16](#ehf212339-bib-0016){ref-type="ref"}, [17](#ehf212339-bib-0017){ref-type="ref"} Individual patient data for patient‐level meta‐analysis were collected from three of the included studies.[12](#ehf212339-bib-0012){ref-type="ref"}, [14](#ehf212339-bib-0014){ref-type="ref"}, [17](#ehf212339-bib-0017){ref-type="ref"}

![Preferred reporting items for systematic reviews and meta‐analyses chart.](EHF2-5-1150-g001){#ehf212339-fig-0001}

Quality of evidence {#ehf212339-sec-0014}
-------------------

No randomized controlled trials comparing MitraClip vs. medical therapy alone were identified. Of the six studies included in the meta‐analysis, four performed prospective enrolment at least in one of the two arms and two included multicentre registries. All studies appraised were from specialized tertiary referral centres. Only one report was published as an abstract.[17](#ehf212339-bib-0017){ref-type="ref"} With the exception of two studies,[16](#ehf212339-bib-0016){ref-type="ref"}, [17](#ehf212339-bib-0017){ref-type="ref"} the other studies included \>50 patients in each group of treatment. Four studies exclusively enrolled patients with functional MR[14](#ehf212339-bib-0014){ref-type="ref"}, [15](#ehf212339-bib-0015){ref-type="ref"}, [17](#ehf212339-bib-0017){ref-type="ref"} while the remaining studies included both functional and degenerative MR.[12](#ehf212339-bib-0012){ref-type="ref"}, [13](#ehf212339-bib-0013){ref-type="ref"}, [16](#ehf212339-bib-0016){ref-type="ref"} From the study of Swans *et al*., only outcome data for functional MR were included. [15](#ehf212339-bib-0015){ref-type="ref"} Otherwise, all patients collected for patient‐level meta‐analysis were affected by functional MR. All but one report[12](#ehf212339-bib-0012){ref-type="ref"} used a propensity score matching in order to minimize imbalance in key baseline characteristics between the MitraClip and medical therapy alone groups. All studies explicitly stated a priori inclusion criteria.

Demographics characteristics {#ehf212339-sec-0015}
----------------------------

Baseline characteristics of overall population and according to the included different studies are summarized in *Tables* [1](#ehf212339-tbl-0001){ref-type="table"} and [2](#ehf212339-tbl-0002){ref-type="table"}, respectively. Overall, 2121 participants who were treated with MitraClip (*n* = 833) or conservative therapy (*n* = 1288) were included. Patients enrolled were predominantly male (78%) and characterized by advance age (median age 71 years), high estimated surgical risk (median logistic EuroSCORE 21% and median Society of Thoracic Surgeons score 11%) and a high burden of co‐morbidities (i.e. chronic kidney disease 45%, chronic obstructive pulmonary disease 45%, diabetes mellitus 45%, a history of previous myocardial infarction 25%, and percutaneous coronary intervention 49%). Despite optimal medical therapy, all patients were symptomatic for dyspnoea, with 95% in New York Heart Association Class III--IV. The mechanism of MR was functional in 93% of patients with 67% of ischaemic aetiology. With the exception of one report, the patients\' baseline characteristics were well matched between the two treatment groups in all studies.[12](#ehf212339-bib-0012){ref-type="ref"}

###### 

Baseline clinical profile of included patients (for study level, all data are reported as continuous or percentages with median and first and third inter‐quartiles; for patient level, as median or percentages)

  -------------------------------------------------------------------------------------------
  Characteristics                               Study‐level cohort\   Patient‐level cohort\
                                                (*n* = 2121)          (*n* = 344)
  --------------------------------------------- --------------------- -----------------------
  Age, years                                    71 (65--82)           74 (67--80)

  Male gender                                   78 (72--81)           81 (67--88)

  Body mass index, kg/m^2^                      23 (22--29)           25 (23--27)

  Logistic EuroSCORE, %                         21 (18--23)           22 (20--24)

  STS score, %                                  11 (8--12)            12 (9--13)

  Previous smoker                               28 (23--45)           33

  Hypertension                                  36 (32--45)           40

  Hyperlipidaemia                               37 (32--43)           33

  Diabetes mellitus                             45 (43--56)           39

  Atrial fibrillation                           45 (43--65)           49

  Chronic obstructive pulmonary disease         45 (43--90)           72

  Chronic kidney disease                        45 (43--64)           50

  Dialysis                                      9 (2--7)              8

  Coronary artery disease                       67 (64--71)           71 (69--81)

  Previous myocardial infarction                25 (24--38)           29

  Previous percutaneous coronary intervention   49 (43--54)           54

  Ischaemic heart disease                       67 (64--81)           70 (68--74)

  Functional mitral regurgitation               93 (91--97)           100

  History of acute pulmonary oedema             17 (12--20)           13

  NYHA Class III--IV                            95 (90--97)           91 (89--96)

  ICD/CRT                                       ---                   74

  ICD                                           ---                   88
  -------------------------------------------------------------------------------------------

CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; STS, Society of Thoracic Surgeons: predicted risk of operative mortality.

###### 

Baseline clinical profile of enrolled patients according to different studies included in the meta‐analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                         Number of patients   Functional MR   Age (years)   Male gender   STS score (%)   Logistic score (%)   Chronic kidney disease   Coronary artery disease    Chronic obstructive pulmonary disease   Atrial fibrillation   NYHA Class III--IV   LV ejection fraction\                                                                    
                                                                                                                                                                                                                                                                                                                      (%)                                                                             
  ------------------------------------------------------------- -------------------- --------------- ------------- ------------- --------------- -------------------- ------------------------ ------------------------- --------------------------------------- --------------------- -------------------- ----------------------- ----- ----- ---- ---- ----- ----- ---- ---- ----- ----- --------- ---------
  Swaans *et al*.[12](#ehf212339-bib-0012){ref-type="ref"}      139                  59              92            93            76 ± 10         73 ± 10              68                       54                                       13.5 ± 9                       4.34 ± 4             23.9 ± 16             18.7 ± 13.2        40    31   51   76   22    32    52   41   88    86    37 ± 15   34 ± 17

  Velázquez *et al*.[13](#ehf212339-bib-0013){ref-type="ref"}   351                  953             70            93            76 ± 11         69 ± 13              61                       49                                      11.3 ± 7.7                      9.7 ± 8.8               ---                    ---            31    19   51   43   11    7     69   52   85    47    48 ± 14   37 ± 11

  Adamo *et al*.[17](#ehf212339-bib-0017){ref-type="ref"}       33                   33              100           100           71 ± 9          71 ± 12              70                       67                                          ---                            ---                  ---                    ---            61    58   42   36   24    27    48   55   100   100   30 ± 9    30 ± 8

  Giannini *et al*.[14](#ehf212339-bib-0014){ref-type="ref"}    60                   60              100           100           75 ± 8          76 ± 8               70                       63                                       4.9 ± 4.2                      3.8 ± 2.6            21.1 ± 14             20.9 ± 12.6        48    33   43   28   25    20    35   43   73    75    37 ± 15   35 ± 11

  Armeni *et al*.[15](#ehf212339-bib-0015){ref-type="ref"}      232                  151             100           100           71 ± 10         71 ± 11              73                       74                                          ---                            ---                  ---                    ---            ---   ---  64   54   25    21    33   33   ---   ---   34 ± 13   32 ± 10

  Asgar *et al*.[16](#ehf212339-bib-0016){ref-type="ref"}       50                   42              100           100           75 ± 9          68 ± 16              74                       77                                          ---                            ---                  ---                    ---            ---   ---  78   71   ---   ---   58   64   98    21    38 ± 16   32 ± 14
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are mean ± SD or %.

LV, left ventricle; MR, mitral regurgitation; MT, medical therapy; NYHA, New York Heart Association; PMVR, percutaneous mitral valve repair with MitraClip.

In order to compare the effect of MitraClip with that of medical therapy among patients with functional MR only, we performed a [meta‐analysis using individual participant data](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847645/). Data from 344 patients with functional MR were collected for individual patient data analysis and matched after propensity score: 172 (50%) were treated with MitraClip and 172 (50%) conservatively. All reported baseline clinical characteristics of the individual patient‐level data cohort were similar to those of the overall cohort (*Table* [1](#ehf212339-tbl-0001){ref-type="table"}). Baseline echocardiographic parameters are detailed in *Table* [3](#ehf212339-tbl-0003){ref-type="table"}. The overall study population showed a severely impaired left ventricular systolic function with a median ejection fraction of 24% (23--36%). Individual patient data meta‐analysis further confirmed left ventricular systolic dysfunction with severely dilated left ventricle and atrial chambers and increased systolic pulmonary artery pressure (*Table* [3](#ehf212339-tbl-0003){ref-type="table"}).

###### 

Baseline echocardiographic profile (for study level, all data are reported as continuous or percentages with median and first and third inter‐quartiles; for patient level, as median or percentages)

  Parameters                           Study‐level cohort (*n* = 2121)   Patient‐level cohort (*n* = 344)
  ----------------------------------- --------------------------------- ----------------------------------
  LV end‐diastolic volume, mL                        ---                          187 (148--224)
  LV end‐diastolic volume \> 200 ml                  ---                                20
  LV ejection fraction, %                        24 (23--36)                       30 (25--38)
  LV ejection fraction \< 25%                        ---                                33
  LA area, cm^2^                                     ---                           30 (25--35)
  SPAP, mmHg                                         ---                           47 (40--55)
  SPAP \> 60 mmHg                                    ---                                30

LA, left atrium; LV, left ventricle; SPAP, systolic pulmonary artery pressure.

MitraClip procedure and in‐hospital outcome {#ehf212339-sec-0016}
-------------------------------------------

Procedural results and in‐hospital adverse events are defined in *Table* [4](#ehf212339-tbl-0004){ref-type="table"}. Overall procedural time, defined as the time from trans‐septal access with the guide catheter to guide removal from the vein, was 140 min. There was no procedural mortality or clip embolization. Profuse bleeding that required multiple transfusions were 13% (9--20%), whereas the incidence of new onset of atrial fibrillation occurred in 1% (0.5--4%). According to individual patient data, acute procedural success rate was 93%, with only two patients in whom it was not possible to implant a clip. In 61% of cases, a single clip was implanted; in 36% two clips; and in 3% three clips. Stroke, pericardial tamponade, myocardial infarction, and urgent cardiovascular surgery for adverse events were not observed. Vascular complication occurred in 20% while the incidence of acute renal failure was very low (1%). Pre‐discharge echocardiography showed a residual MR \> 2 grade in 12% of patients.

###### 

Procedural results and in‐hospital outcomes in MitraClip patients (for study level, all data are reported as continuous or percentages with median and first and third inter‐quartiles; for patient level, as median or percentages)

  Characteristics                     Study‐level cohort (*n* = 2121)   Patient‐level cohort (*n* = 344)
  ---------------------------------- --------------------------------- ----------------------------------
  Number of clip                                                       
  1                                                 ---                                61
  2                                                 ---                                36
  3                                                 ---                                3
  Procedural mortality                               0                                 0
  Procedural time, min                        140 (118--180)                     140 (118--180)
  Pericardial tamponade                             ---                                0
  Urgent cardiovascular surgery                     ---                                0
  Vascular complication                             ---                                21
  Bleeding requiring transfusion                13 (9--20)                             7
  Stroke                                            ---                                0
  New onset of atrial fibrillation              1 (0.5--4)                             2
  Acute renal failure                                                                  1
  Myocardial infarction                             ---                                0
  Clip embolization                                  0                                 0
  MR grade at discharge                                                
  1+/2+                                         80 (78--82)                       88 (87--91)
  3+                                            19 (18--23)                        12 (8--13)
  4+                                             1 (0--1)                              0

MR, mitral regurgitation.

Survival outcomes {#ehf212339-sec-0017}
-----------------

Clinical follow‐up was documented at a median of 400 days (376 to 480). There was a total of 133 all‐cause mortality: 52 (30%) in the PMVR arm and 81 (47%) in the conservative group (*P* \< 0.001). The summary estimate comparing PMVR using MitraClip System combined with medical therapy and medical therapy alone showed a statistically significant relative risk reduction of death from any cause in favour of PMVR with homogeneity across reports \[odds ratio (OR) 0.79, 95% CI: 0.68--0.92, *P* = 0.002; *I* ^2^ = 96%; *τ* ^2^ = 0.03\] (*Figure* [*2*](#ehf212339-fig-0002){ref-type="fig"} *A*). Through the follow‐up period, heart failure re‐hospitalization data were reported in three studies: 26 (48%) patients in the PMVR arm and 47 (60%) patients in the conservative group (*P* = 0.02). Overall, a significant difference in survival free from readmission due to cardiac disease favouring MitraClip over medical therapy alone was observed with homogeneity across reports (OR 0.73, 95% CI: 0.59--0.91, *P* = 0.005; *I* ^2^ = 89%; *τ* ^2^ = 0.03) (*Figure* [*2*](#ehf212339-fig-0002){ref-type="fig"} *(B)*).

![Random‐effects meta‐analysis of percutaneous mitral valve repair vs. conservative therapy for study‐level analysis. Forest plot showing the result of meta‐analysis of percutaneous mitral valve repair vs. conservative therapy for the primary outcome of death from any causes (A) and for the secondary outcome of re‐hospitalization (B) after a median follow‐up of 400 days (376 to 480). The estimate of the odds ratio (OR) of each study corresponds to the middle of the squares, and the horizontal line shows the 95% confidence interval (CI). For each subgroup, the sum of the statistics, along with the summary OR, is represented by the middle of the solid diamonds. A test of heterogeneity between the trials within a subgroup is given below the summary statistics. OMT, optimal medical therapy; IV, instrumental variable estimation; SE, standard error.](EHF2-5-1150-g002){#ehf212339-fig-0002}

Subgroup analysis {#ehf212339-sec-0018}
-----------------

Subgroup analysis was available only for individual patient data (344 participants with functional MR). After a median follow‐up of 304 days (172 to 725), there was evidence of survival benefit for MitraClip in patients with functional MR and among all the main subgroups (*Figure* [*3*](#ehf212339-fig-0003){ref-type="fig"} *A*). The effect in favour of MitraClip was also confirmed for the secondary outcome of re‐hospitalization across all subgroups except for patients with ischaemic aetiology and those with both left ventricle end‐diastolic volume \< 200 and \>200 mL (*Figure* [*3*](#ehf212339-fig-0003){ref-type="fig"} *B*).

![Subgroup analyses from individual patient‐level data for the primary outcome of death from any causes (A) and for the secondary outcome of re‐hospitalization (B) after a median follow‐up of 304 days (172 to 725). Odds ratio (OR) and corresponding confidence intervals for patients subgroups were pooled, and interactions were evaluated by random‐effects meta‐analyses. The vertical dashed line on plot represents the point estimate of OR = 1. Asterisk indicates no significant difference. ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; EF, ejection fraction; LVED, left ventricle end‐diastolic.](EHF2-5-1150-g003){#ehf212339-fig-0003}

Discussion {#ehf212339-sec-0019}
==========

The current meta‐analysis represents an attempt to assess the outcomes of PMVR vs. conservative therapy in patients with heart failure and severe MR.

The main novel findings of this meta‐analysis are summarized as follows: Compared with medical therapy alone, PMVR with MitraClip resulted in a significant relative risk reduction of death from any cause in high‐risk patients with predominantly functional MR and advanced heart failure.Mortality benefits with PMVR over medical therapy were confirmed in patients who only had functional MR and were consistent across all the main subgroups.An overall marked reduction in hospital readmission for cardiovascular disease favouring MitraClip was also observed.The effect in favour of MitraClip for re‐hospitalization was also consistent in patients with functional MR only and among all subgroups except for patients with ischaemic aetiology and those with both left ventricle end‐diastolic volume \< 200 and \>200 mL.

Functional MR is associated with a poor prognosis in heart failure patients with post‐ischaemic or idiopathic dilated cardiomyopathy.[1](#ehf212339-bib-0001){ref-type="ref"} The presence of even mild degrees of functional MR identifies patients with left ventricular dysfunction who have a higher mortality risk than those without MR.[2](#ehf212339-bib-0002){ref-type="ref"} The appropriateness of mitral valve surgery for patients with functional MR remains embroiled in controversy, because functional MR is the consequence and not the cause of left ventricular dysfunction.[6](#ehf212339-bib-0006){ref-type="ref"}, [21](#ehf212339-bib-0021){ref-type="ref"} Moreover, surgical mitral valve repair for functional MR is associated with not negligible perioperative mortality, and the number of patients with severe functional MR who are not referred for surgery because of high surgical risk, advanced age, and co‐morbidities is increasing.[4](#ehf212339-bib-0004){ref-type="ref"}, [5](#ehf212339-bib-0005){ref-type="ref"} The introduction of PMVR with the MitraClip device opened new perspectives for the treatment of patients with severe MR at very high surgical risk.[7](#ehf212339-bib-0007){ref-type="ref"} Although less effective than surgery in reducing MR, the MitraClip showed fewer perioperative adverse events and achieved a similar durable improvement in functional MR.[9](#ehf212339-bib-0009){ref-type="ref"}, [22](#ehf212339-bib-0022){ref-type="ref"} A number of studies have compared the outcomes of MitraClip with those of surgical repair reporting similar survival rates.[12](#ehf212339-bib-0012){ref-type="ref"}, [23](#ehf212339-bib-0023){ref-type="ref"}, [24](#ehf212339-bib-0024){ref-type="ref"} However, these findings should be interpreted with caution, because of higher risk profiles (higher age, lower ejection fraction, and higher predicted mortality) in the MitraClip group than in the surgical repair one. In particular, MitraClip implantation has been shown as an effective adjunctive therapy for patients with advanced heart failure and severe functional MR, offering the chance to obtain a relevant reverse cardiac remodelling and significant improvement in functional class even in highly symptomatic patients with severely dilated hearts.[7](#ehf212339-bib-0007){ref-type="ref"}, [25](#ehf212339-bib-0025){ref-type="ref"}

What remains unknown is whether the PMVR with MitraClip device improves survival in patients with moderate to severe left ventricular failure causing functional MR. Up to now, there are few non‐randomized studies that globally report better survival outcome of PMVR compared with optimal medical therapy in patients with severe MR.[12](#ehf212339-bib-0012){ref-type="ref"}, [13](#ehf212339-bib-0013){ref-type="ref"}, [15](#ehf212339-bib-0015){ref-type="ref"}, [16](#ehf212339-bib-0016){ref-type="ref"} However, most of these studies include a wide spectrum of high‐risk patients with both functional and degenerative MR. Recently, we evaluated clinical outcome of patients with functional MR and reduced left ventricular function treated conservatively compared with those who received MitraClip device.[14](#ehf212339-bib-0014){ref-type="ref"} After propensity analysis, we proved that transcatheter mitral valve repair was superior over conservative treatment. Overall survival rates were 89.7%, 61.4%, and 71.2% at 1, 2, and 3 years in the PMVR groups vs. 64.3%, 51.7%, and 34.9% at 1, 2, and 3 years in the conservative group, respectively (*P* = 0.007).

Therefore, we performed the current meta‐analysis of existing studies to confirm these findings. Six observational reports and \>2121 participants with predominantly functional MR (93%) and high surgical risk were included. Our results highlight the worse outcomes of medically managed patients affected by severe MR and the better survival benefit of those treated with endovascular repair (*P* = 0.03). Furthermore, we performed a [meta‐analysis using individual participant data](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847645/) to clarify the effect of MitraClip vs. medical therapy in patients with only functional MR. Patient‐level analysis confirmed that MitraClip therapy is superior to conservative treatment even in patients with functional MR and advanced heart failure and across all the main subgroups.

In particular, in the cohort of patients with functional MR, mortality benefit with PMVR over medical therapy is independent of age, ischaemic aetiology, presence of implantable cardioverter defibrillator/cardiac resynchronization therapy, and left ventricular ejection fraction and volumes. These finding are in contrast with those of a previous study that reported an increased risk of all‐cause death after MitraClip in patients presenting an ischaemic aetiology or those with severely dilated left ventricle.[26](#ehf212339-bib-0026){ref-type="ref"} However, this study presents several limitations because it included a wide spectrum of high‐risk patients with both functional and degenerative MR. Recently, the results from Transcatheter Valve Treatment Sentinel Pilot Registry, including 452 patients with functional MR who underwent MitraClip procedure in 25 centres across Europe, confirmed our results, reporting no significant differences between the two aetiologies (ischaemic or non‐ischaemic) regarding survival at 1 year follow‐up.[27](#ehf212339-bib-0027){ref-type="ref"}

However, patients with advanced heart failure still have a poor prognosis despite MitraClip implantation. This could be related to advanced stage of evolution of their disease and may inspire researchers to analyse clinical predictors of futility of the MitraClip because of the relevant clinical and economic issues.[23](#ehf212339-bib-0023){ref-type="ref"}, [28](#ehf212339-bib-0028){ref-type="ref"}, [29](#ehf212339-bib-0029){ref-type="ref"} Recent evidences have identified severe right ventricular failure as an independent predictor of cardiovascular mortality in patients with functional MR and advanced heart failure undergoing MitraClip treatment.[28](#ehf212339-bib-0028){ref-type="ref"}, [29](#ehf212339-bib-0029){ref-type="ref"}

Finally, we reported that patients treated with PMVR experienced a lower incidence of readmission due to cardiac disease than did patients treated conservatively (*P* = 0.03). These results are comparable with the data from Lim *et al*. showing a decrease in re‐hospitalization in prohibitive‐surgical‐risk patients after MitraClip implantation.[30](#ehf212339-bib-0030){ref-type="ref"} Transcatheter reduction of MR in these patients translated to significant benefits, including improvements in symptoms and functional status, favourable left ventricle remodelling, and consequently a decrease in hospitalizations.

Interestingly, we proved that the effect in favour of MitraClip for the secondary outcome of re‐hospitalization was robust across all subgroups except for patients with ischaemic aetiology. Our results are consistent with the data reported by Capodanno *et al*. showing a significant worsening in terms of re‐hospitalization in patients presenting with an ischaemic aetiology at 2 years\' follow‐up.[26](#ehf212339-bib-0026){ref-type="ref"} These findings suggest that an ischaemic setting potentially represents a more challenging scenario for percutaneous treatment of MR, stressing the importance of patient selection.

However, to investigate whether PMVR has superior survival benefit over conservative therapy in high‐surgical‐risk patients with functional MR, we need results from randomized clinical trials. The ongoing COAPT (Clinical Outcomes Assessment of the MitraClip Percutaneous Therapy for High Surgical Risk Patients) and MITRA FR (Multicentre Study of Percutaneous Mitral Valve Repair MiraClip Device in Patients with Severe Secondary Mitral Regurgitation) studies will provide important additional evidence.

Conclusions {#ehf212339-sec-0020}
===========

The late outcome of MitraClip compared with medical therapy alone is crucial as the number of MitraClip continues to increase over the last few years. The current meta‐analysis shows that MitraClip is a safe therapeutic option for selected high‐surgical‐risk patients with severe functional mitral regurgitation and entails better survival outcomes than do conservative treatment. The hypothesis that transcatheter mitral valve repair has superior survival benefits vs. conservative therapy in high‐surgical‐risk patients with left ventricular dysfunction and functional MR needs to be tested with randomized clinical trials, and results from the ongoing clinical trials (COAPT and MITRA FR) will be helpful in this setting.

Study limitations {#ehf212339-sec-0021}
-----------------

The present study has many limitations. First of all, no randomized trials were included in the meta‐analysis but only observational studies owing to the lack of publications comparing PMVR with conservative treatment. Second, meta‐regression analysis results should be read as hypothesis generating only, which need to be confirmed in larger studies. Third, one study included patients from a non‐published report but simply from abstract.[17](#ehf212339-bib-0017){ref-type="ref"} Finally, clinical heterogeneity may derive from different selections of population in each centre: Actually, this innovative technique is reserved to patients at different stages of heart failure. In all but one report,[12](#ehf212339-bib-0012){ref-type="ref"} a propensity score matching was used to minimize imbalance in key baseline characteristics between the MitraClip and medical therapy groups.
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